Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations

chi.scholasticahq.com/article/115793

Reading this great manuscript by colleagues Katie Gatewood, our amazing superstar Zahra M, PharmD, MBA, BCOP, FHOPA, and Bhagirath Dholaria, MD! This will help our patients and decrease the financial…

Fun fact: United Health makes $7B more in a month than the two largest PE firms in healthcare (KKR & Blackstone) make in a year combined (~$30B to $23B)

👇🏾💡Here’s a novel finding from our #NESTTrial 🪺.

Lymphocytes go⬇️in patients with MSS.
🚕🚕🚕 “Recruitment” from blood to go to where the action is (tumor).

Lymphocytes go⬆️in patients with MSI-High.
“Normalization”.

➕🆕🔢“Kasi” formula 2.0➡️MSI from a simple CBC using NLR.

🫘Revised Sapporo criteria for diagnosis of anti phospholipid antibody syndrome

✅Atleast one clinical
Criteria plus

✅Positive antiphospholipid antibody within 3 years of diagnosis aPl related clinical event

#ISNWCN

❓How to best manage immune.related AEs
Impact of immunosuppressive agents on the
management of irAEs of immune checkpoint blockers
doi.org/10.1016/j.ejca…
👉Infliximab & Methotrexate: no impact on survival
👉Steroids alone: worse outcome
🧐Better early use of immunosuppressants?

HCA reports almost $1 billion more in charity care to Medicare than to its shareholders, drawing more taxpayer money statnews.com/2024/04/08/hca… via STAT

American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer jamanetwork.com/journals/jamao…

Out today in Translational Oncology !
With Vinay Prasad MD MPH , we explore the results of S1801 trial:
- resectable stage III-IV melanoma
- pembro-first strategy (3 cycles then 15) vs adjuvant only strategy
paper open access 👉sciencedirect.com/science/articl…
+ graphical abstract👇
a 🧵
1/

I’m looking forward to discussing ‘Who to transplant with T cell lymphoma?’
#EBMT2024
Few/no Randomised data (yet) & heterogenous (>30 diff entities & classification challenging)
However Rx options in R/R setting remain disappointing (unavailable) & few clinical trials
The EBMT

Breast cancer has the highest incidence worldwide (ASR,crude rate)
-ER+/HER2- ~75% cases
-stage II+III ~45-50% cases (CH)

➡️ NATALEE (3 years adjuvant ribociclib) could affect up to 30 - 35 % of newly diagnosed breast cancer

BUT we found many concerns❗️

Our analysis is here👇

#Neoadjuvant therapy for #melanoma is the new kid on the block. Our analysis provides guidance on the choice of regimen. Read on! jamanetwork.com/journals/jamao…
Doctors Weigh Patient Goals Instead of ‘Dictating’ Melanoma Treatment curetoday.com/view/doctors-w… via CURE Today

Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

🌍Refractory pulmonary fungal infection
🖊️Lewis white
▶️diagnostic work up
▶️proposed medical management
#EBMT24 #hematology #LEUKEMIA #fungal #infection
#azole

🌍invasive fungal infection in HSCT #EBMT24
▶️complexity of managing
▶️antifungal drug profile
▶️breakthrough IFI and suggested empirical therapy
#hematology #LEUKEMIA #fungal #infection #BMT

Glucocorticoids (GC), like dexamethasone and prednisolone, are widely used in medicine, but how do they actually work?

This is really impressive work (Auger et al.), which figured it all out

There are two mechanisms: a slow, broad response, which depends on transcriptional…

The importance of ABO in platelet refractoriness, an often overlooked option
buff.ly/49ulvzy

The real money in the healthcare system is spent on middlemen that you never see, and that is how they like it. The CEO of Change Healthcare is paid $9.5 Million a year and has never saved a patient's life. The CEO's of Large insurance companies make 20+ Million a year and I…

Cell & Gene Therapy Approvals (US/EU)
2009-2024

haematology: 20 (FDA), 10 (EMA)
neurology: 4 (FDA), 3 (EMA)
ophthalmology: 1 (FDA), 2 (EMA)
oncology: 4 (FDA), 1 (EMA)
gastroenterology: 1 (EMA)
dermatology: 3 (FDA)
immunodeficiency: 1 (FDA), 1 (EMA)
musculoskeletal: 1 (FDA), 1…

Here is the summary from the three „New Drugs on the Horizon“ sessions at #AACR24 once again. What an impressive mix of drug modalities. And for the NCEs it clearly shows that chirality is the rule not the exception. The future of NCE drug discovery is bright and chiral.

UnitedHealth pays out a staggering $662 million worth of medical claims every day, and generated $4 billion last year solely from interest income on its massive portfolio of bonds and other securities. tinyurl.com/294rzsf3